130 results about "Disease markers" patented technology

Methods for analyte detection with magnetic sensors are provided. Aspects of the methods include producing a magnetic sensor device having a magnetically labeled analyte from a sample, such as a serum sample, bound to a surface of a magnetic sensor thereof; and obtaining a signal, e.g., a real-time signal, from the magnetic sensor to determine whether the analyte is present in the sample. Also provided are devices, systems and kits that find use in practicing the methods of the invention. The methods, devices, systems and kits of the invention find use in a variety of different applications, including detection of biomarkers, such as disease markers.

A method includes a step of identifying candidate miRNA-mRNA complexes where an mRNA sequence from a set of mRNA sequences stably hybridizes to a miRNA from a set of miRNA sequences. The candidate miRNA-mRNA complexes have stably hybridizing sub-regions of a downstream region to portions of a 5′ miRNA section and stably hybridizing sub-regions of an upstream region to portions of a 3′ miRNA section. Candidate mRNA and / or miRNA sequences are identified as sequences that form candidate microRNA-mRNA complexes. Differences between expression levels between candidate mRNA and / or miRNA sequences in subjects having a disease and subjects not having the disease are determined for each candidate mRNA and / or miRNA sequence to identify candidate mRNA sequences and / or miRNA sequences. The expression levels of each candidate RNA disease markers are compared to controls such that deviation of expression levels of the candidate RNA disease markers from the controls indicates presence of the disease.

The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the β-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the Aβ region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, β-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.

The invention relates to an electrochemiluminescence immunosensor for detecting beta-amyloid protein and construction of the electrochemiluminescence immunosensor. The sensor comprises a magnetic glassy carbon electrode and Fe3O4-expoxy, a mesoporous carbon @Ru(bpy)32+ / beta-amyloid protein antibody composite nanometer composite material, beta-amyloid protein to be detected with different concentrations and a gold nanorod-beta- beta-amyloid protein aptamer nanometer composite material, wherein the Fe3O4-expoxy, the mesoporous carbon @Ru(bpy)32+ / beta-amyloid protein antibody composite nanometer composite material, beta-amyloid protein to be detected with different concentrations and the gold nanorod-beta- beta-amyloid protein aptamer nanometer composite material are synthesized on the surface of the magnetic glassy carbon electrode in sequence. Compared with the prior art, the electrochemiluminescence immunosensor has the advantages that the constructing method is simple, detection on Alzheimer's disease markers (beta-amyloid protein and the like) is high in speed, high in sensitivity, high in specificity, low in detection limit, wide in detection range and the like, and the application of the electrochemiluminescence immunosensor provides a new thought for early diagnosis of the Alzheimer's disease and detection of markers of other diseases.

This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and / or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and / or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.

It is an object of the present invention to find substances that can be used as disease markers for atopic dermatitis and the present invention provides a method for determining atopic dermatitis, including measurement of the expression of specific proteins and / or their genes in skin cells and / or skin tissues, wherein the specific proteins change their expression with inflammation caused by atopic dermatitis or change their expression according to the degree of predisposition to atopic dermatitis. The present invention also provides a kit for determining the degree of inflammation of atopic dermatitis or risk of developing atopic dermatitis, as well as a method for determining substances effective in the treatment and / or prevention of atopic dermatitis.

The invention belongs to the field of metal organic framework materials used for analyzing and detecting disease markers and specifically relates to a fluorescence sensor for detecting uric acid and apreparation method thereof. Different concentrations of uric acid solutions with the same volume are vibrated and mixed with an NH2-BDC-MOF nanosheet solution, an uricase solution and an o-phenylenediamine solution, the uric acid solutions are stood under 37 DEG C for 30 minutes, and fluorescence signals are detected to construct a fluorescence signal-concentration work curve; then fluorescence signals in a sample are detected and substituted into the work curve to achieve the purpose of quantitatively analyzing uric acid in the sample. The method has the advantages of quickness, flexibilityand high efficiency.

The invention discloses a near-infrared window fluorescent imaging agent containing diazosulfide and a fluorene ring and a preparation method thereof. A modifiable group is introduced into the fluorene ring of the fluorescent compound, increased modifiable sites can be used for connection of different bioactive substances, water solubility and biological compatibility can be improved, and the application range in the biomedical field can be expanded. The fluorescent imaging agent has the advantages of high fluorescence intensity, no toxicity, good biocompatibility, and the like, and has excellent application prospects. The invention also discloses the application of the fluorescent imaging agent in the field of brain glioma, systemic angiography and sentinel lymph node dissection. In addition, the imaging agent has good modificability, and also can be used for in-vitro detection of various disease markers, in-vivo diagnosis and surgical navigation treatment of breast cancer, prostate cancer and colon cancer and other cancer, evaluation of curative effect after tumorectomy, and the like.

The invention relates to preparation of protamine gold nanoclusters and application in analogue enzyme color comparison and fluorescence detection. The protamine gold nanoclusters not only have activity of horseradish peroxidase and oxidase, but also have fluorescent characteristic. Hereby, a protamine gold nanocluster analogue enzyme visual color comparator and a fluorescence sensor are established respectively and are used for detecting heavy metal ions. The protamine gold nanoclusters are prepared simply and conveniently, are low in cost, and have excellent fluorescence stability and chemical stability, and the shortcomings that fluorescence of traditional dyestuff is short in service life, photobleaching occurs easily and the like can be overcome; a fluorescence method is high in sensitivity and good in stability, and expensive instruments are not required; and analogue enzyme catalytic color comparison is sensitive and environment-friendly, and can be used for field real-time monitoring. The protamine gold nanoclusters are expected to be expanded and applied to detection and analysis of related substances in the fields of environment and biomedicines and disease markers, and have wide application prospect.

The invention belongs to the field of applying a metal organic framework to analysis and detection of a disease marker, and particularly relates to a fluorescent sensor for detecting inorganic pyophosphatase and its preparation method. Through reacting different concentrations of inorganic pyophosphatase solution with pyrophosphate, Cu-BDC-MOF nanosheet solution, hydrogen peroxide solution and terephthalic acid solution are added and incubated at 37 DEG C for 30 minutes; fluorescent signals of inorganic pyophosphatase with different concentrations is detected, a working curve is structured, and the fluorescent sensor is prepared. The fluorescent signal of the inorganic pyophosphatase in a sample is detected by the fluorescent sensor, and then corresponding to the working curve, thus the quantitative analysis of the inorganic pyophosphatase in the sample is realized. The detection method is high in selectivity, fast, sensitive and high-efficient.

The invention provides a mass spectrometry detecting method for a serum polypeptides, comprising sample preparation, data-independent mass spectrometry acquisition, and data processing. According to the mass spectrometry detecting method for the serum polypeptides, a data-independent mass spectrometry acquisition method for serum peptidomics samples is developed, and the parent ion distribution ofthe sample by pre-analytical experiment on serum samples is obtained, thereby obtaining an optimal variable isolation window. Each condition and each step cooperate with each other by optimizing thepreparation method of the polypeptideomics sample, the mass spectrometry acquisition method, and the data processing method, and finally, the number of the detection of the polypeptide, the reproducibility of the identification, and the quantitative accuracy are significantly improved. The method of the invention has the characteristics of high throughput, high reproducibility, and high accuracy,and is suitable for analysis of large-scale clinical serum samples and detection of disease markers, thereby having wide application prospects and great market value.

The invention includes prognostic and diagnostic methods and compositions for characterizing disease states, biopsy samples, biological samples, cells, and tissues. In various embodiments of the invention, a bioassay may be used to analyze the activity of the androgen receptor (AR) in human prostate epithelial (HPE) cells derived from patient samples. The activity of the AR may be used to characterize the sample in regard to AR activity. Characterization of a sample may be useful in classify the sample and / or in determining a treatment regiment. In other embodiments, a sample may be compared to other known samples to identify other distinguishing characteristics, such as disease markers, and / or determine a treatment regiment based on the comparison of samples.

The invention relates to a surface enhanced Raman scattering technology-based composite material and a preparation method thereof. The composite material comprises microspheres modified with first target molecules on the surfaces and a second component modified with Raman signal molecules and second target molecule-modified polymers on the surface. In a solution containing a substance to be detected, the substance to be detected, the microspheres and the second component are bonded to the second target molecules through the first target molecules so that the composite material which can be easily precipitated through centrifugation is obtained. The invention also discloses the preparation method and a use of the composite material. The composite material can be used for detecting a human prostate-specific antigen (PSA), a human ferrohemoglobin (Hb), a procalcitonin (PCT) or disease markers (such as tumor markers, cardiovascular disease markers, senile dementia markers, mycoplasma and chlamydia), can effectively reduce false positive and false negative effects and has advantages of high sensitivity, simpleness, fastness and low cost.

The invention relates to interdisciplinary fields of biology, medicine, material, chemistry and virology, and discloses a homogeneous immunoassay based method for synchronous fluorescence detection of multiple disease markers. The method comprises the specific steps of: first, covalently coupling different fluorescent dyes with antibodies of different disease markers, and dissolving in water or other solvents to obtain a reaction solution A; second, mixing the solution A with a graphene oxide solution to obtain a reaction solution B; third, mixing the reaction solution A, the reaction solution B and water or other solvents to obtain a solution C; and fourth, adding an antigen solution into the mixed solution C, transferring the mixed solution to a fluorescence cuvette, measuring synchronous fluorescence intensity, and conducting quantitative analysis and multi-index analysis and diagnosis. The method has advantages of simpleness, rapidness, high sensitivity, high specificity and low cost, and can realize high-throughput detection, multiple index analysis diagnosis and remote diagnosis.

The invention discloses a saliva diagnostic sensor. The sensor comprises a metal surface and a composite nano coiled material distributed on the metal surface; the composite nano coiled material refers to metal nano particles generated when the metal surface is wrapped with a coiled graphene material. The invention further discloses a preparation method and application of the saliva diagnostic sensor. The saliva diagnostic sensor excellently strengthens the Raman scattering effect and maintains good stability in saliva, the detection process for disease markers in the saliva is simple, and the sensor is low in cost and reliable in result and has a wide application prospect range in early screening diagnose of diseases of stomach cancer and the like for mass groups.

The present invention provides a method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue. The invention also provides a method of identifying novel targets for therapeutic intervention and disease markers. Novel cancer targets are provided.

Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair.

A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCLIO, CXCLl 1, CXCLl 3, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.

The present invention provides a sensor for detection of disease markers, and methods for detecting a disease marker, using a conductive hydrogel modified with a biorecognition element. In one embodiment, the present invention provides a sensor having a substrate; at least one electrode contacting the substrate; a nanoporous membrane covering the electrode; and a biorecognition element selected from the group consisting of a peptide, an antibody, an enzyme, and an aptamer, wherein the biorecognition clement is covalently bound to the electrode, or covalently bound to a PEDOT random copolymer embedded within the nanoporous membrane.

The invention discloses a fast detector for ultra-trace disease markers, relating to a detection technology. The fast detector comprises a 37 DEG C constant-temperature heating system, a flow injection system and a detection control system, wherein in the 37 DEG C constant-temperature heating system, a temperature sensor detects a heating cup closely pressed by semiconductor heating sheets at real time, and continuously adjusts the semiconductor heating sheets to achieve the 37 DEG C constant-temperature heating function, thereby providing a 37 DEG C incubation environment for the biological reaction; a peristaltic pump is used for realizing flow injection and finishing automatic sampling so as to reduce human error and shorten detection time; the detection control system comprises a photoelectric conversion unit, a photon counting unit and a central processing and control unit; and a high-sensitive photomultiplier tube is used for realizing weak light detection, and the detection cavity is well shielded. By using the high-speed programmable logic device FPGA (field programmable gate array) to realize photon pulse counting, the invention has the advantages of random setting of counting time and counting digit capacity, sensitive counting and small error, thereby achieving the purpose of detecting ultra-trace substances.

The present invention relates to a use of a protein nanoparticle-based hydrogel, and more particularly, to a use of a protein nanoparticle-based hydrogel capable of highly sensitive and simultaneous multi-detection of disease markers by using a hydrogel to which a protein nanoparticle representing a disease marker detection probe is immobilized.

The present invention provides a sensor for detection of disease markers, and methods for detecting a disease marker, using a conductive hydrogel modified with a biorecognition element.

The invention relates to a surface-enhanced Raman immunoassay planar sensor as well as a preparation method and application thereof. The sensor comprises an SERS planar substrate and an SERS label, the preparation method of the sensor is applied to molecular detection of disease markers. The SERS planar substrate is prepared by modifying dopamine, a to-be-detected object antibody and bovine serumalbumin on the surface of a two-dimensional nanogold array. The SERS label is prepared by modifying report molecules on the surfaces of gold nanoparticles, packaging bovine serum albumin, and modifying dopamine and the to-be-detected object antibody. The sensor has the advantages that (1) in sample detection, the planar sensor is cleaned through leaching, so that convenience and quickness are realized; (2) the ordered nanogold array generates uniform hot spots, and the signal reproducibility is good; (3) the Raman detection sensitivity can be enhanced through the approaching of the SERS substrate and the label; and (4) the specificity of the immune sandwich method is strong, qualitative and quantitative detection of target molecules can be realized by combining the immune sandwich method with SERS, the response is sensitive, and the detection time is short.

Methods for analyte detection with magnetic sensors are provided. Aspects of the methods include producing a magnetic sensor device having a magnetically labeled analyte from a sample, such as a serum sample, bound to a surface of a magnetic sensor thereof; and obtaining a signal, e.g., a real-time signal, from the magnetic sensor to determine whether the analyte is present in the sample. Also provided are devices, systems and kits that find use in practicing the methods of the invention. The methods, devices, systems and kits of the invention find use in a variety of different applications, including detection of biomarkers, such as disease markers.

The invention discloses an Alzheimer's disease detection marker and a detection method thereof. A group of serum difference proteins provided by the invention can be used to detect the Alzheimer's disease, and when the group of serum difference proteins is used in the Alzheimer's disease detection, the group of serum difference proteins can improve the specificity and the accuracy of detection, has certain objectivity, and is better than single disease markers. 26 Serum difference proteins are obtained through comparing Alzheimer's disease patient's serum and heavy contrast serum by adopting high-flux proteomics, and a result of comparison with contrast shows that the number of expression up-regulation proteins is 6, and the number of expression down-regulation proteins is 20. All above proteins are detected one by one through ELISA, or are detected one by one or simultaneously through adopting a protein chip technology in order to determine the concentration change of the detected serum difference proteins, and the concentration change can be used as a basis for diagnosing the Alzheimer's disease. The detection method disclosed in the invention has higher specificity, sensitivity and accuracy than present Alzheimer's disease detection measuring scales.

An autonomous molecular computer that, when coupled to a molecular model of a disease, is capable of disease diagnosis. The computer preferably performs such diagnosis by detecting one or more disease markers. For example, optionally and preferably the molecular computer checks for the presence of over-expressed, under-expressed and mutated genes, applies programmed medical knowledge to this information to reach a diagnostic decision.

The invention relates to a mass spectrometry method for a complete glycosylated peptide fragment based on quasi-multistage spectrum and an application thereof in early diagnosis of liver cancer. The method mainly comprises the following five steps: 1) enrichment of a glycosylated peptide fragment; 2) sample preparation of a deglycosylated peptide fragment-complete glycosylated peptide fragment; 3)mass spectrometry of the deglycosylated peptide fragment-complete glycosylated peptide fragment; 4) spectrogram data retrieval of the deglycosylated peptide fragment-complete glycosylated peptide fragment; and 5) based on the above, through combination of glycosylation site and complete glycopeptide quantification technology, realizing glycosylation refined difference analysis of a cancer patientand a normal person and screening potential disease markers. The method realizes refined analysis of human protein glycosylation, and has important application potential in screening the tumor markers.

Disease specific markers, in particular cancer markers, can be detected by electrophoretically separating proteins and protein complexes from a biological sample on a protein binding polymeric membrane in a low conductivity, water-miscible organic solvent buffer. Electrophoretic separation profiles representing different diseases can be produced, and used in the diagnosis or prognosis of these diseases.

This invention discloses an approach is improve the strength and reproducibility of the signal generated in FTAs using solid-phase microextraction (SPME) through the design of an approach to generate the plasmonically-enhanced signal for SERS, surface-enhanced infrared (SEIRA), and other enhanced spectroscopies. The design incorporates: (1) a particle-particle coupling strategy that is triggered by the selective capture of an analyte to a particle that has been immobilized on a membrane and has been modified to act as a capture substrate; (2) the selective tagging of the captured analyte by a nanoparticle also designed to generate an amplified plasmonic signal upon tagging; and (3) the incorporation of an internal nanoparticle standard to account for fluctuations in flow rates and flow paths. Collectively, these developments improve the accuracy and precision of the analysis as well as the SPME analysis accurately, improving the ease-of-use for a number of different SPME-based measurements, including, for example, those focused on disease markers using immunoassays and a range of other assay formats.